Vaccines play an essential role in keeping humans healthy. Innovative approaches to their use include the utilization of plasmid DNA encoding sequences to express foreign antigens. DNAhsp65 from Mycobacterium leprae is suitable for this purpose due to its ability to elicit a powerful immune response. Controlled release systems represent a promising approach to delivering vaccines. In this work, we used liposomes or PLGA systems to deliver DNAhsp65 to treat the pulmonary fungal infection Paracoccidioidomycosis. Both formulations modulated a protective immune response and reduced the pulmonary fungal burden even in the groups receiving less than four times the amount of the DNAhps65 entrapped within the nanoparticles. Although both systems had the same effective therapeutic results, the advantage of the liposome formulation was that it was administered intranasally, which may be more easily accepted by patients. These systems are a great alternative to be considered as adjuvant vaccine therapy for systemic mycosis.
INTRODUCTION
Vaccines are considered successful applications for maintaining human health, especially in combating infections. They are used to protect and even treat a number of diseases, including mycosis, whose cases have increased over the past few years. [1] [2] [3] Innovative approaches in vaccine development are using plasmid DNA encoding sequences to express foreign antigens, such as peptides and proteins, to elicit a specific immune response. The DNA vectors may be used in applications as preventive or therapeutic DNA vaccines for various health disorders, including cancer and infectious diseases. [4] [5] [6] DNA vaccines incorporate genes that codify immunomodulatory molecules to increase the protective response through the modulation of the cellular and humoral * Author to whom correspondence should be addressed.
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immune responses. 5 Heat-shock proteins (HSPs) are suitable molecules to be applied as antigens because of their interference in both innate and adaptive immunity. 7 HSP65 from Mycobacterium leprae is a member of the HSP family and is used as genetic vaccine (DNAhsp65) in immune modulation for prophylaxis and therapy against parasitic infection and other animal diseases. 2 6 8 9 It is known that a vaccine's ability to develop specific and proper immunological protection must be related to efficient adjuvants. 10 The design of rational adjuvant delivery systems that act both as a vehicle for the antigen while also stimulating the immunological system has become an area of intensive research. [11] [12] [13] The nanoscale-controlled release systems represent a promising approach to deliver vaccines and present advantages over administering the conventional form of the naked plasmid DNA vaccine. Among the improvements for vaccines produced by these systems, protection against the antigen's degradation in vivo and the optimization of the antigen's capture within the nanoparticles by the antigen-presenting cells [12] [13] [14] may be highlighted. The biodegradable nanoparticles, such as liposomes and polylactic-co-glycolic acid (PLGA), are attractive for preparing nanocarriers for vaccines due to their ability to slowly and gradually control the release of an antigen. 15 The liposomes used as delivery systems for DNA vaccines have the capacity to protect DNA against the problem of degradation in a physiological microenvironment, while improving the activation of innate immunity by allowing the DNA to enter directly into the endosomal compartment. 16 Moreover, the phospholipids properly chosen to be used in the preparation of liposomes can preclude the induction of antibody production against themselves, thereby preventing the appearance of unwanted side effects in patients caused by repeated injections. 17 Liposomes encapsulating DNA vaccines used as boosters were used to elicit strong mucosal T cell responses in BALB/c mice after intranasal administration of HbsAg. 18 This approach potentiates the activation of a protective immunity to complete the clearance of the vaccinia virus from the animals' lungs and enhance CD8+, IFN-gamma cell frequencies and levels of IgA and IgG before viral challenge.
Biodegradable polymers were successfully used to prepare nanoparticles to deliver various bioactive molecules. 11 19 Among the different biodegradable polymers, the poly(D,L-lactic-co-glycolic) acids (PLGA) act as a potent adjuvant. They can provide protection against the in vivo destruction of immunogenic molecules, resulting in a decrease in the amount needed to elicit a protective immune response. 11 20 The DNA vaccine formulated within PLGA microparticles reduced the severity of the respiratory syncytial virus challenge in the experimental pulmonary disease model, preserving the ability of the DNA to protect against virus infection and replication. This DNA-PLGA formulation reduced lung eosinophilia and restored the CD8+ T cell recruitment, avoiding the induction of IL-4 and IL-5 during the challenge compared to non-vaccinated animals. 19 The mechanism involved in potentiating the action of an antigen should be related to the activation of dendritic cells by these nanoparticles. The PLGA nanoparticles that carry the antigen encapsulated or conjugated on its surface potentiate the antigen ability to activate both human and mouse dentritic cells, making it about twentyfold more potent than free antigen. 21 Since the nanoparticles are readily taken up by dendritic cells, a huge amount of antigens are captured more efficiently, whereas free antigens suffer diffusion around the physiologic medium resulting in a decrease of effective immune activation. 11 20 21 In this report we will discuss the use of two different nanoparticle adjuvants, liposomes and PLGA, to deliver the DNAhsp65 vaccine to treat the mycosis murine model of Paracoccidioidomycosis (PCM), a health problem in Latin America that represents 51.2% of total deaths among the most common systemic mycoses. Chronic PCM affects the lungs, presenting a granulomatous inflammatory response and the production of a Th1 pattern of cytokines. 22 23 2. METHODS
DNAhsp65 Plasmid Construction
The DNAhsp65 vaccine was obtained as previously described by Farmacore Biotechnology Ltd. (Ribeirão Preto, S.P., Brazil). 24 In brief, the pVAX1 vector (Invitrogen, Carlsbad, CA, U.S.A.) was digested with BamHI and NotI (Invitrogen, Carlsbad, CA, U.S.A.) and a fragment of the Mycobacterium leprae hsp65 gene was inserted. The pVAX1 vector without the hsp65 insert was used as a control. The plasmids were obtained from transformed DH5 Escherichia coli and purified using the Endofree Plasmid Mega kit (Qiagen, Valencia, CA, U.S.A.). All samples were subjected to quantification of LPS using a commercial kit (QCL-1000 ® Chromogenic LALEndpoint Assay Cambrex Corporation, Walkersville, MD, U.S.A.). The values found in all samples were below than 0.1 endotoxin units/ g, as recommended by the European and U.S. pharmacopeias and the purity of DNA preparations was verified by electrophoresis (1% agarose gel).
Entrapment of DNAhsp65 Plasmid
Onto Microspheres
Farmacore Biotechnology Ltd. obtained microspheres using the double-emulsion/double-solvent evaporation technique. Its characterization was described in a previous study. 24 In brief, 30 ml of a dichloromethane solution containing 400 mg of PLGA polymer 50:50 [Resomer RG 505, molecular weight (MW) 78,000, from Boehringer Ingelheim, Ingelheim, Germany] and trehalose dymicolate were emulsified with an aqueous inner solution containing pVAX1 or pVAX1-hsp65 DNA, using a T50 UltraTurrax homogenizer (IKA, Labortechnik, Germany) to produce a primary water-in-oil emulsion. This emulsion was then mixed with 100 ml of an external aqueous phase containing 3% polyvinyl alcohol (Mowiol 40-88, Aldrich Chemicals, Wankee, WI, U.S.A.) as a surfactant to form a stable water-in-oil-in-water emulsion. The mixture was stirred for six hours with a Eurostar homogenizer (IKA, Labortechnik, Germany) for solvent evaporation. Microspheres were collected and washed three times with sterile water, then freeze-dried and stored at 4 C. The plasmid encapsulation rate was determined by resuspending 10 mg of microspheres in 0.5 ml of methylene chloride and 0.2 ml of TE buffer (Tris 10 mM, EDTA 1 mM, pH 8.0). Samples were incubated at 37 C under rotation endto-end for one hour and centrifuged. The DNA was measured in the upper aqueous phase as described before using the GeneQuant II (Pharmacia Biotech, Piscataway, NJ, The liposome preparation and its characterization by Farmacore Biotechnology Ltd. were described in a previous study. 24 Egg phosphatidylcholine (EPC), 1,2-dioleoyl-snglycero-3-phosphoethanolamine (DOPE) and 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) were purchased from Avanti Polar Lipids. The cationic liposomes were prepared in three steps: (i) preparation of liposomes according to Bangham's method, 25 (ii) dehydration by lyophilization and (iii) hydration to obtain dehydrated-hydrated vesicles (DRVs) described by Kirby and Gregoriadis (1994). 26 In brief, the required amounts of all lipid stock solutions in chloroform (EPC/DOPE/DOTAP 50/25/25% molar) were mixed and dried to a thin film using a rotary evaporator in a 650 mmHg vacuum for one hour. The dried lipid film was hydrated with water at 30 C above its phase transition temperature. The liposomes were extruded through two stacked polycarbonate membranes (100 nm nominal diameter) 15 times at a nitrogen pressure of 12 kgf/cm 2 . According to the Farmacore Biotechnology Ltd. the PLGA preparations were stable during the experiments.
Mice
Male BALB/c mice (6-8 weeks old) were obtained from the University of São Paulo (Ribeirão Preto, S.P., Brazil) and kept under standard laboratory conditions with water ad libitum and 12 hours dark/light cycle. All experiments involving animals were approved by the Bioethical Committee of the University of Brasília (UnB, Brasília, D.F., Brazil) and conducted in accordance with their guidelines.
Fungal Strain and Intratracheal Infection
Yeast cells of the virulent strain Pb18 were grown for five days in liquid Yeast Peptone Dextrose (YPD, w/v: 2% peptone, 1% yeast extract, 2% glucose) medium at 37 C and 150 rpm, washed three times and then resuspended with Phosphate Buffer Solution (PBS, NaCl 136.8 mM, KCl 2.7 mM, KH 2 PO 4 0.9 mM, Na 2 HPO 4 6.4 mM). Mice were anaesthetized i.p. with 200 L of a solution containing 80 mg/kg of ketamine and 10 mg/kg of xylazine (both from União Química Farmacêutica, Brazil). After approximately 10 minutes, their necks were hyperextended and the trachea was exposed at the level of the thyroid. Each animal received 50 L inoculums containing 3 × 10 5 viable yeast cells injected intratracheally with a 26-gauge needle. Viability was determined with Janus Green B vital dye 27 (Merck, Darmstadt, Germany) and was higher than 80%. The incisions were sutured with 5-0 silk.
Treatments
Treatments were initiated after 30 days of infection, and occurred twice at a 15-day interval. The route of treatment administrations were by intramuscular (I.M.) or intranasally (I.N.). For I.N. liposomal treatment, each animal received a volume of 50 L slowly instilled in their nostrils using a micropipette to guarantee that all the volume was inhaled.
According to the treatments received, the animals were placed in the following experimental groups: Non-infected animals (NON-INFECTED group) and infected animals treated only with the empty nanoparticles without the plasmids (PLGA or LIPOSOMAL groups) were used as controls. After 15 days of the last dose, the animals were euthanized by CO 2 asphyxiation. The samples of lungs, spleen and serum were collected for posterior analysis. Significative alterations on weight or behavior were not noted on treated groups.
Histopathological Analysis and Fungal Burden Determination in Lungs
To evaluate the lesions' progress, lung fragments were removed and fixed in 10% formalin for six hours, dehydrated in alcohol, and embedded in paraffin. Serial 5 m sections were stained with hematoxylin-eosin (HE) to visualize the fungus and granulomatous appearances, with masson trichrome to quantify collagen and silver for fungal load evaluation. The lung fungal burdens were measured by quantitative counts of colony-forming units (CFU) of P. brasiliensis and lung fragments were homogenized in 1 mL of PBS (pH 7.2). A total of 500 L of the homogenates were plated onto brain heart infusion agar (BHI agar), supplemented with 4% horse serum, 5% P. brasiliensis 192 (Pb192) culture filtrate 28 and gentamicyn 40 mg/L (Gentamycin Sulfate, Schering-Plough, Rio de Janeiro, Brazil). The plates were incubated at 36 C, and the number of colonies was counted after incubation for 21 days. Results were expressed as number of CFU ± standard error of the mean (SEM) per gram of lung tissue (CFU/g). 
Lymphoproliferation and Cytokine Production Assays
Total spleen cell proliferative responses to Concanavalin-A (Con-A) were studied by [H 3 ]-thymidine incorporation as previously described. 29 Spleen cells were disrupted in RPMI 1640 supplemented with 2 mM l-glutamine, 1 mM sodium pyruvate, 5% non-essential amino acids 2 beta-mercaptoethanol, streptomycin (100 g/mL), and 5% fetal bovine serum. Cells were washed twice in RPMI medium, counted, added to 96-well plates at a cell density of 3 × 10 5 cells/well and subsequently stimulated with Con-A (4 g/mL). The experiments were performed in triplicate at a final volume of 200 L/well. After 48 hours of incubation at 37 C under 5% CO 2 , cultures were pulsed for 12 hours with 1 Cie/well with H 3 -labeled thymidine and then harvested. Incorporation of H 3 -thymidine was measured using a liquid scintillation counter (Beckman Instruments Inc., Fullerton, CA, U.S.A.); data were expressed as means ± SEM of counts per minute of H 3 -thymidine incorporation. Supernatants of spleen cells cultured from experimental groups were used to perform cytokine production assays. The cytokines interleukin-4 (IL-4), interleukin-10 (IL-10), interleukin-12 (IL-12), and interferon-gamma (IFNwere measured using a commercial ELISA (enzyme linked immunosorbent assay) kit (according to the guidelines established by BD Biosciences, San Diego, CA, U.S.A.). The cytokine level was calculated based on a standard curve provided by the commercial kit. Data were expressed as the mean (log 10 ± SEM.
Analysis of Anti-HSP65-Specific Antibodies
The specific IgG1 and IgG2a isotypes were measured by ELISA. Ninety-six well plates (Nunc) were sensitized with rhsp65 protein (250 ng/100 L well) overnight at 4 C. Plates were blocked with 1:100 dilution of mouse serum for 2 h at 37 C. After washing with PBS plus 0.05% Tween 20, peroxidase-labeled antibodies specific for mouse IgG1 or IgG2a isotypes (Sigma) were diluted to 1:5000 and added for 2 h at 37 C. The plates were washed seven times with PBS plus 0.05% Tween 20 and incubated with H 2 O 2 and o-phenylenediamine for reaction development. Reactions were stopped by the addition of 20 L of H 2 SO 4 2 N. Optical densities were determined at 490 nm in an ELISA reader (BioRad, model 2550, CA, U.S.A.).
Nitric Oxide (NO) Production Assays
The concentration of nitrite (NO 2− ) in total non-stimulated spleen cell supernatants was measured by a microplate Griess assay as described previously. 30 NO 2 concentration in culture supernatants was used as an indicator of NO generation and measured with the Griess reagent (1% sulfanilamide, 0.1% naphthylethylene diamine dihydrochloride, 2.5% H 3 PO 4 . In brief, 100 L of the culture supernatants was added to an equal volume (v/v) of Griess reagent and incubated at room temperature for 10 minutes. Absorbance at 540 nm was determined with a microplate reader. NO 2− concentration was determined using a standard curve of 1-200 M of NaNO 2 . Conversion of absorbance to M of NO was deduced from a standard curve by using a known concentration of NaNO 2 diluted in RPMI medium. All determinations were performed in triplicate and expressed with mean ± SEM of M of NO 2 . The serum nitrate concentration was determined by reducing nitrate to nitrite enzymatically using nitrate reductase as described previously. 31 The total amount of nitrite was then determined using the Griess method. The results are reported as M of NO 3 .
Statistical Analysis
All experiments were repeated twice independently. Data from the different experimental groups were compared using a one-way ANOVA test and multiple comparisons with Dunnet's post-test. All calculations and plotting were done using PRISM 5.0 (Graph Pad Software for Science, San Diego, CA., U.S.A.). The results were considered significant when p < 0 05. All results were presented as means ± SEM.
RESULTS

Pulmonary Histopathological Analysis and Quantitative Measurement of Fungal Burden in Lungs of Animals Infected with P. Brasiliensis and Treated with DNAhsp65 Within Liposomal and PLGA Formulations
To evaluate the P. brasiliensis infection in the experimental model, we analyzed the pulmonary histopathological and fungal burden recovery. The examination of lung sections of animals from infected pVAX1, pVAX1 PLGA and liposome groups revealed a clear inflammatory response with the presence of mononuclear inflammatory infiltrate with granuloma and fungal cells (infected group, Fig. 1(A) ). There was no difference among the animals from all the groups described above. Progression of the infection was observed mainly in the lungs and was characterized by a diffuse inflammatory response as well as a significant presence of P. brasiliensis in this organ from both groups. The histological examination of lungs from the DNAhsp65, DNAhsp65 PLGA and liposomal DNAhsp65 groups showed a discrete peribronchiolar mononuclear inflammatory infiltrate, with few fungal cells and low lung damage (DNAhsp65 PLGA group, Fig. 1(B) 
In (A), areas of inflammatory infiltrate with granuloma (HE, 100×). In (B), discrete peribronchiolar inflammatory infiltrate (HE, 100×). In (C), extensive fibrotic area associated with inflammatory infiltrate (Masson, 100×). In (D), discrete peribronchiolar and perivascular fibrosis (Masson, 100×). In (E), numerous fungal cells in areas of inflammatory infiltrate (Groccott, 100×). (F) Sparse fungal cells in discrete inflammatory infiltrate (Groccott, 100×). Fungal burden recovery from lungs of all animal experimental groups after the treatments (G).
The bars depict means ± SEM of CFU obtained from experimental groups. * P < 0 05 is indicated with lines. The data represent a typical experiment, which has been repeated twice with similar results.
(Infected group, Fig. 1(C) ) in the lung tissue of the infected group. In contrast, the DNAhsp65 PLGA group showed less inflammation, a discrete peribronchiolar and perivascular fibrosis (DNAhsp65 PLGA group, Fig. 1(D) ), a clearly lower number of yeast cells, and very little collagen deposition. Figures 1(E) (Infected group) and (F) (DNAhsp65 PLGA group) show numerous fungal cells in areas of mononuclear inflammatory infiltrate ( Fig. 1(E) ) and sparse fungal cells in discrete inflammatory infiltrate ( Fig. 1(F) ).
The decrease in the number of yeast cells in the DNAhsp65 treated group was confirmed by P. brasiliensis CFU quantification. The fungal loads recovered from DNAhsp65 groups (DNAhsp65, liposomal DNAhsp65 and DNAhsp65 PLGA) were significantly lower than observed in the infected and pVAX1 (pVAX1, liposomal pVAX1 and pVAX1 PLGA) groups (Fig. 1(G) ). The pVAX1, liposomal pVAX1 and pVAX1 PLGA groups showed a pulmonary fungal burden similar to that of the infected group. Liposomal and DNAhsp65 PLGA therapies (20 g/mice) significantly reduced the fungal burden as did the DNAhsp65 treatment (400 g/mice).
Humoral Immune Response of Mice Infected with P. Brasiliensis and Treated with DNAhsp65 Formulations
To characterize the mechanisms responsible for the therapeutic effects of DNAhsp65, we investigated the antibody response to hsp65 in BALB/c mice infected with the virulent P. brasiliensis, after receiving the different treatments. Anti-HSP65 antibodies were detected in the sera of mice from infected and pVAX1 groups at significantly lower levels than in mice treated with DNAhsp65, although the same groups are able to produce both subtypes of IgG, IgG1 (Fig. 2(A) ) or IgG2 ( Fig. 2(B) ). These results showed that the DNAhsp65 could stimulate the immune response, increasing specific antibody production. The animals showed similar antibody levels in DNAhsp65 therapies: DNAhsp65 (400 g/mice), liposomal DNAhsp65 (20 g/mice) and DNAhsp65 PLGA (20 g/mice), with higher levels of IgG2a than IgG1.
Effect of DNAhsp65 Treatment Within Different Formulations on Cell Proliferation and Determination of the Cytokine Profile
To determine if the immune response of treated animals was modulated by DNAhsp65 within the different formulations tested, we examined splenocyte proliferation and cytokine production. The spleen cell proliferation of infected and DNAhsp65-treated mice was recovered after Con-A stimulation when compared with the infected and non-treated mice (Fig. 3) . The same figure also shows that mice from the infected and pVAX1 groups displayed a significantly low ability to proliferate in the presence of stimuli. Cytokine production was examined by monitoring the levels of IL-10, IL-12, IFN-and IL-17 in culture supernatants of splenocytes from all experimental groups. As shown in Table I non-infected group (data not show). IL-17 production is different in infected and non-infected groups (Table I) . DNAhsp65, DNAhsp65 PLGA and liposomal DNAhsp65 groups had increased production of IL-17 compared to non-infected and infected groups ( Table I ). The IL-4 levels were similar in all groups analyzed (data not shown).
NO Production After Treatment with DNAhsp65 Formulations
We evaluated the production of NO through NO 2 and NO 3 concentrations in the serum and supernatants of spleen cell cultures, respectively. The animals treated with DNAhsp65, liposomal DNAhsp65 and DNAhsp65 PLGA showed significantly high amounts of both NO 2 and NO 3 compared to the non-infected group of mice. The infected and pVAX1 groups did not present alterations in the amounts of NO 2 ( Fig. 4(A) ) and NO 3 ( Fig. 4(B) ) compared to the non-infected group (Figs. 4(A) and (B)). The same results were observed with liposomal pVAX1 and pVAX1 PLGA (Figs. 4(A) and (B) ). These data suggest that the treatments with liposomal and DNAhsp65 PLGA (20 g/mice) are able to prime the immune response of mice as well as the treatment with DNAhsp65 (400 g/mice) and can treat them for infection by P. brasiliensis and fungi lyses mediated by NO.
DISCUSSION
The use of vaccines to prevent or even treat mycosis has been studied, envisioning the circumvention of the increased rates of systemic fungal infections worldwide. [1] [2] [3] Immunostimulatory molecules, such as DNA-or peptidebased vaccines are the approaches used for these purposes. 3 6 32 Once the main goal of these strategies is to stimulate the immunological system to produce cytokines to fight against the pathogens, the use of nanostructured sustained release systems to deliver these molecules is also investigated. 11 33 For this report, we tested the effects of two different nanoparticles to deliver the DNAhsp65 vaccine in the treatment of an experimental model of PCM.
The utilization of sustained release systems to deliver immunomodulatory molecules is of interest to avoid in vivo degradation and promote its slow release. 11 33 Biodegradable polymers and liposomes can lead the antigen to be ready for uptake into the antigen-presenting cells by endocytosis, resulting in a gradual stimulation of the immune system. 12 14 33 These nanoscale particles are appropriate for use as vehicles for heat shock proteins (HSP). 34 The HSPs, such as HSP65 from Mycobacterium leprae, are used to elicit prophylactic and therapeutic effects on some experimental diseases, including tuberculosis, leishmaniasis and PCM. 2 6 35 36 Previous data from our group showed that the DNAhsp65 vaccine triggered immunoprotection against fungal infection, observed by the reduction of pulmonary fungal burden in the animals when administered with DNAhsp65, both to immunize or to treat the P. brasiliensis infection. 2 6 Moreover, DNAhsp65-based immunotherapy modulated a protective immune response, observed by a dominant Th1 cell response. The Th1 pattern, mediated by IL-12, is considered to be protective against infection with the P. brasiliensis fungus and other pathogenic fungi. 1 23 37 Considering the advantages of sustained delivery systems as vehicles for immunomodulatory molecules, we decided to evaluate the protective effect of the nanostructurated DNA-hsp65 vaccine administered via two different routes: PLGA (I.M.) and liposome (I.N.) nanoparticles. Our first result demonstrated a significant reduction of the pulmonary fungal burden from infected mice treated with DNA-hsp65. However, the number of CFU from animals that received a PLGA-or liposomebased vaccine presented a dramatic reduction, even receiving less than four times the amount of the DNAhps65 used in the nanoformulations compared with naked DNAhsp65. These findings concur with the results of several studies showing the higher efficiency of the vaccine-encapsulated HSP65 compared with the naked DNA vaccine. Coelho et al. (2006) showed that the encapsulated MHSP/TDM is more immunogenic than naked DNAhsp65 and has great potential to improve vaccine effectiveness against leishmaniasis and tuberculosis. 36 A single dose of a vaccine based on DNA encoding mycobacterial hsp65 protein plus TDM-loaded PLGA microspheres protects mice against a virulent strain of M. tuberculosis. This smart formulation also allowed a tenfold reduction in the DNA dose compared to naked DNA. 38 One important effect of PCM mycosis is the formation of fibrotic granuloma in mouse lungs, which are considered a serious consequence of this and other fungal infections. Here, in the histological analyses, we observed the presence of an inflammatory response with aggregates of fibrous tissue and leucocytes, which is characteristic for this disease in untreated animals. The histological examination of lungs from animals treated with PLGA or DNAhsp65 liposomal formulation has shown compact and organized granuloma. Since these granuloma are defense Table I . Cytokines profile.
Non-infected (pg/mL) Infected (pg/mL) pVAX1 (pg/mL) DNAhsp65 (pg/mL) DNAhsp65 PLGA (pg/mL) DNAhps65 LIP (pg/mL) mechanisms against the pathogen, and given the small size of this structure, it would be more effective to protect the host by retaining and avoiding fungal dissemination. 39 The reduction of the fungal burden and the organized granuloma formation in infected mice could be related to the increase in the production of protective cytokines. Mice treated with DNAhsp65, PLGA or liposomal DNAhsp65 produced significantly higher levels of IFN-and IL-12, which ensure resistance to fungal infection. 40 On the other hand, no significant differences were noted for the IL-4 and IL-10 cytokine levels. Resistance to fungal infection, including the fungus P. brasiliensis, has been related to IFN-and other Th1-type cytokines, mainly IL-12, 23 37 40 while susceptibility has been linked to the preferential production of the Th2-type cytokines, i.e., interleukin (IL)-4, IL-5, and IL-10. 37 41 42 Conversely, it has been reported that a high level of humoral immune response is associated with increased disease dissemination. 43 Another important finding observed in our results was the increase in IL-17 production by the DNAhsp65 or PLGA and liposome DNAhsp65 treated groups. The increase in the levels of IL-17 cytokine is associated with an impairment of T regulatory lymphocyte expansion in the P. brasiliensis murine model, thereby increasing Th17 immunity. 44 Higher levels of IgG2 antibodies than those of IgG1 were detected in the groups receiving different formulations for the DNAhsp65. These results support other results regarding the increase of inflammatory immune response. Furthermore, a high level of splenocyte stimulation was induced in the infected mice treated with the DNAhsp65 in the presence of Con-A, almost similar to the non-infected group. On the other hand, the mice from the infected and pVAX1 or nanoparticle empty groups displayed a significantly low ability to proliferate in the presence of stimuli. 6 Another important finding was the elevated concentration of NO in the serum and spleen cell cultures from mice treated with DNAhsp65, PLGA and liposomal DNAhsp65. NO is known to work as a potent microbicide factor and its secretion is related to the elimination of fungus and protection for the host. Animals treated with DNAhsp65, liposomal DNAhsp65 and DNAhsp65 PLGA showed significantly high amounts of both NO 2 and NO 3 compared to the non-infected group of mice. The infected and pVAX1 groups did not show alterations in the amounts of NO 2 and NO 3 compared to the non-infected group. The same results were observed with liposomal pVAX1 and pVAX1 PLGA. These data suggest that the treatments with liposomal and DNAhsp65 PLGA (20 g/mice) are able to prime the immune response of mice, as can the treatment with DNAhsp65 (400 g/mice), and can be used for infections from P. brasiliensis, and fungi lyses mediated by NO.
Adjuvant and immunostimulatory therapy is a promising approach to improving the treatment of systemic fungal infections such as PCM, whose drug therapy is usually prolonged and associated with toxic side effects and relapses. 11 33 Meira et al. (1996) tested glucan as an immunostimulant in the treatment of PCM in patients. The results indicated that despite being more seriously ill, the patients who received glucan had a stronger and more favorable response to therapy. 45 Immunization with peptide P10, derived from gp43, and chemotherapy were used together in an attempt to improve treatment of PCM and prevent relapses. The combined treatment showed an added protective effect after intratracheal challenge with P. brasiliensis. 32 The peptide P10 had its immunostimulatory activity increased by its formulation within PLGA nanoparticles, reducing its amount twentyfold without losing its adjuvant potency.
11
Both systems showed the same effective therapeutic results and the same stability during the experiments, but the liposome formulation presented the advantage of being administered intranasally, which may be more easily accepted by the patients. The results demonstrated that these systems are a great alternative to be considered as vaccine adjuvant therapy for systemic mycosis. 
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